Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds - PubMed
5 days ago
- #genetics
- #drug targets
- #psychiatric disorders
- Leveraging genetics to prioritize drug targets and compounds for psychiatric disorders.
- Used GWAS of ADHD, bipolar disorder, depression, and schizophrenia for drug enrichment analyses.
- Conducted molecular trait analyses using transcriptomic and proteomic datasets from brain and blood.
- Prioritized drug targets and compounds, highlighting glutamate signaling and psychotropic medications.
- Found genetic support for drugs like clozapine, duloxetine, and lithium.
- Suggested drug repurposing opportunities, such as cholinergic drugs for ADHD and estrogen modulators for depression.
- Identified reduced CYP2D6 expression in schizophrenia, indicating potential poor drug response.
- Demonstrated the utility of genetics in drug development and repurposing for psychiatric disorders.